LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Dovitinib | 10.0 | uM | LJP5 | 3 | E19 | 72 | hr | 1401 | 2039 | 4223 | 0.4828 | 0.2259 |
| SK-BR-3 | Enzastaurin | 10.0 | uM | LJP5 | 1 | D13 | 72 | hr | 1401 | 4049 | 4223 | 0.9588 | 0.9383 |
| SK-BR-3 | Enzastaurin | 10.0 | uM | LJP5 | 2 | D13 | 72 | hr | 1401 | 4094 | 4223 | 0.9694 | 0.9543 |
| SK-BR-3 | Enzastaurin | 10.0 | uM | LJP5 | 3 | D13 | 72 | hr | 1401 | 4485 | 4223 | 1.0620 | 1.0928 |
| SK-BR-3 | Erlotinib | 10.0 | uM | LJP5 | 1 | M19 | 72 | hr | 1401 | 1831 | 4223 | 0.4336 | 0.1522 |
| SK-BR-3 | Erlotinib | 10.0 | uM | LJP5 | 2 | M19 | 72 | hr | 1401 | 2190 | 4223 | 0.5186 | 0.2795 |
| SK-BR-3 | Erlotinib | 10.0 | uM | LJP5 | 3 | M19 | 72 | hr | 1401 | 2159 | 4223 | 0.5112 | 0.2685 |
| SK-BR-3 | Foretinib | 10.0 | uM | LJP5 | 1 | H07 | 72 | hr | 1401 | 1406 | 4223 | 0.3329 | 0.0016 |
| SK-BR-3 | Foretinib | 10.0 | uM | LJP5 | 2 | H07 | 72 | hr | 1401 | 1264 | 4223 | 0.2993 | -0.0487 |
| SK-BR-3 | Foretinib | 10.0 | uM | LJP5 | 3 | H07 | 72 | hr | 1401 | 1386 | 4223 | 0.3282 | -0.0055 |
| SK-BR-3 | R406 | 10.0 | uM | LJP6 | 1 | C13 | 72 | hr | 1401 | 3004 | 4223 | 0.7113 | 0.5679 |
| SK-BR-3 | R406 | 10.0 | uM | LJP6 | 2 | C13 | 72 | hr | 1401 | 3017 | 4223 | 0.7144 | 0.5726 |
| SK-BR-3 | R406 | 10.0 | uM | LJP6 | 3 | C13 | 72 | hr | 1401 | 3081 | 4223 | 0.7296 | 0.5952 |
| SK-BR-3 | Pictilisib | 10.0 | uM | LJP6 | 1 | D19 | 72 | hr | 1401 | 1542 | 4223 | 0.3651 | 0.0498 |
| SK-BR-3 | Pictilisib | 10.0 | uM | LJP6 | 2 | D19 | 72 | hr | 1401 | 1382 | 4223 | 0.3273 | -0.0069 |
| SK-BR-3 | Pictilisib | 10.0 | uM | LJP6 | 3 | D19 | 72 | hr | 1401 | 1565 | 4223 | 0.3706 | 0.0579 |
| SK-BR-3 | Gefitinib | 10.0 | uM | LJP6 | 1 | N07 | 72 | hr | 1401 | 1900 | 4223 | 0.4499 | 0.1767 |
| SK-BR-3 | Gefitinib | 10.0 | uM | LJP6 | 2 | N07 | 72 | hr | 1401 | 1715 | 4223 | 0.4061 | 0.1111 |
| SK-BR-3 | Gefitinib | 10.0 | uM | LJP6 | 3 | N07 | 72 | hr | 1401 | 1700 | 4223 | 0.4026 | 0.1058 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP5 | 1 | O01 | 72 | hr | 1401 | 519 | 4223 | 0.1229 | -0.3128 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP5 | 2 | O01 | 72 | hr | 1401 | 1027 | 4223 | 0.2432 | -0.1327 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP5 | 3 | O01 | 72 | hr | 1401 | 1199 | 4223 | 0.2839 | -0.0718 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP6 | 1 | O01 | 72 | hr | 1401 | 547 | 4223 | 0.1295 | -0.3029 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP6 | 2 | O01 | 72 | hr | 1401 | 1000 | 4223 | 0.2368 | -0.1423 |
| SK-BR-3 | Geldanamycin | 10.0 | uM | LJP6 | 3 | O01 | 72 | hr | 1401 | 771 | 4223 | 0.1826 | -0.2235 |